Xencor Financials

XNCR Stock  USD 25.30  0.76  2.92%   
Based on the analysis of Xencor's profitability, liquidity, and operating efficiency, Xencor Inc is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, Xencor's Non Currrent Assets Other are relatively stable compared to the past year. As of 11/26/2024, Net Receivables is likely to grow to about 15 M, while Total Current Liabilities is likely to drop slightly above 65.8 M. Key indicators impacting Xencor's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio4.37.3565
Way Down
Slightly volatile
Investors should never underestimate Xencor's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Xencor's cash flow, debt, and profitability to make informed and accurate decisions about investing in Xencor Inc.

Net Income

(119.78 Million)

  
Understanding current and past Xencor Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Xencor's financial statements are interrelated, with each one affecting the others. For example, an increase in Xencor's assets may result in an increase in income on the income statement.

Xencor Stock Summary

Xencor competes with Edgewise Therapeutics, Keros Therapeutics, Monte Rosa, Mineralys Therapeutics,, and Erasca. Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California. Xencor operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 254 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS98401F1057
CUSIP98401F105
LocationCalifornia; U.S.A
Business Address465 North Halstead
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.xencor.com
Phone626 305 5900
CurrencyUSD - US Dollar

Xencor Key Financial Ratios

Xencor Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets670.3M703.2M838.2M846.3M952.7M491.0M
Other Current Liab9.0M13.8M19.4M9.3M23.6M24.7M
Net Debt(39.6M)(151.9M)(109.5M)5.7M29.6M31.1M
Retained Earnings(296.4M)(365.7M)(283.1M)(338.3M)(464.4M)(441.2M)
Accounts Payable10.2M9.0M14.0M10.1M13.9M7.2M
Cash50.3M163.5M143.5M53.9M53.8M57.9M
Net Receivables22.1M23.9M66.4M29.0M11.3M15.0M
Other Current Assets6.5M10.7M23.9M23.3M18.1M19.1M
Total Liab77.0M130.8M104.7M118.8M283.6M297.7M
Total Current Assets558.4M637.7M424.4M675.3M623.2M326.5M
Short Term Debt2.2M3.8M34.0M9.4M9.8M12.0M
Intangible Assets14.4M16.0M16.5M18.5M18.7M13.6M
Common Stock569K580K595K601K611K464.5K
Other Assets713K212K5.7M613K705.0K1.1M
Net Tangible Assets578.8M556.5M717.0M709.0M815.3M471.4M
Capital Surpluse845.4M887.9M937.5M1.0B1.2B761.6M
Net Invested Capital593.2M572.4M733.5M727.5M689.8M647.5M

Xencor Key Income Statement Accounts

The reason investors look at the income statement is to determine what Xencor's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201920202021202220232024 (projected)
Interest Expense17.7M0.07.5M36.8M42.3M44.4M
Total Revenue156.7M122.7M275.1M164.6M168.3M94.4M
Gross Profit38.1M122.7M275.1M164.6M(85.3M)(81.0M)
Operating Income9.5M(76.8M)43.8M(82.5M)(138.6M)(131.7M)
Ebit9.5M(76.8M)43.8M(82.5M)(137.4M)(130.5M)
Research Development118.6M169.8M192.5M199.6M253.6M266.3M
Ebitda13.8M(71.0M)51.3M(73.7M)(125.9M)(119.6M)
Income Before Tax27.2M(69.3M)82.6M(54.5M)(120.4M)(114.4M)
Net Income26.9M(63.5M)82.6M(55.2M)(126.1M)(119.8M)
Income Tax Expense312K(5.8M)(7.5M)673K5.8M6.1M
Cost Of Revenue118.6M169.8M7.5M8.8M253.6M266.3M
Interest Income13.6M7.3M849K4.8M13.7M7.0M
Tax Provision0.0312K(288K)673K(415K)(394.3K)
Net Interest Income13.6M7.3M849K4.8M13.7M7.6M

Xencor Key Cash Accounts

201920202021202220232024 (projected)
Change To Inventory(1.4M)3.5M(5.9M)1.4M1.3M1.3M
Change In Cash24.1M113.2M(20.1M)(89.5M)228K216.6K
Free Cash Flow53.3M(18.8M)(32.8M)(18.9M)63.9M67.1M
Depreciation4.3M5.8M7.5M8.8M11.5M12.1M
Other Non Cash Items(4.1M)(21.3M)(22.4M)(26.9M)(20.1M)(19.1M)
Capital Expenditures11.0M13.8M16.0M43.4M21.3M11.4M
Net Income26.9M(69.3M)82.6M(55.2M)(126.1M)(119.8M)
End Period Cash Flow50.3M163.5M143.5M53.9M54.2M57.9M
Investments(39.9M)114.0M(29.4M)(119.7M)116.6M122.4M
Change Receivables(9.6M)(11.7M)11.3M(54.3M)(48.9M)(46.4M)
Change To Netincome32.1M5.3M39.1M22.0M25.3M18.3M

Xencor Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Xencor's current stock value. Our valuation model uses many indicators to compare Xencor value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Xencor competition to find correlations between indicators driving Xencor's intrinsic value. More Info.
Xencor Inc is rated below average in return on equity category among its peers. It is rated fifth in return on asset category among its peers . At this time, Xencor's Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Xencor by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Xencor Inc Systematic Risk

Xencor's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Xencor volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Execute Function
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Xencor Inc correlated with the market. If Beta is less than 0 Xencor generally moves in the opposite direction as compared to the market. If Xencor Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Xencor Inc is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Xencor is generally in the same direction as the market. If Beta > 1 Xencor moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Xencor Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Xencor's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Xencor growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(0.0783)

At this time, Xencor's Price Earnings To Growth Ratio is relatively stable compared to the past year.

Xencor November 26, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Xencor help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Xencor Inc. We use our internally-developed statistical techniques to arrive at the intrinsic value of Xencor Inc based on widely used predictive technical indicators. In general, we focus on analyzing Xencor Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Xencor's daily price indicators and compare them against related drivers.

Additional Tools for Xencor Stock Analysis

When running Xencor's price analysis, check to measure Xencor's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xencor is operating at the current time. Most of Xencor's value examination focuses on studying past and present price action to predict the probability of Xencor's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xencor's price. Additionally, you may evaluate how the addition of Xencor to your portfolios can decrease your overall portfolio volatility.